This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dec. 20, 2012 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments for diseases associated with protein misfolding and apoptosis, today announced that Dr.
John W. Commissiong, CSO will present results of its Parkinson's disease neurorestoration animal studies at the
OneMedForum SF 2013 conference on
Tuesday, January 8, 2013 at
1:40pm PT. The conference will take place at the Sir Francis Drake Hotel in
San Francisco, CA.The presentation will be webcast live at the link:
Dr. Commissiong, Amarantus' Chief Scientific Officer, will be presenting results of the Parkinson's experiments including detailed review of behaviour, histology, densitometry and stereology data for MANF and how they compare with results obtained for GDNF. Thereafter, current Amarantus advisor Dr.
Joseph Rubinfeld will provide his views on areas of significant commercial potential for MANF beyond Parkinson's disease.
OneMedForum SF 2013 is an international healthcare conference where emerging private and small cap public companies present to, and meet with investors of all types including high net worth individuals, alternative investors, asset managers, hedge funds, institutional investors, and venture capitalists.
John Commissiong, Chief Scientific Officer
Dr. Commissiong has served as the Chief Scientific Officer and a Director of Amarantus since co-founding the Company in 2008. Dr. Commissiong was Head of the Neurotrophic Factors Group and the Neural Transplantation lab at the National Institute of Neurological Disorders and Stroke. He has an over 30 year career in researching disorders of the Central Nervous System. Dr. Commissiong's lab discovered MANF in 2003. The work pioneered by Dr. Commissiong has led to significant advancements in the field of astrocyte-neuron biology. Dr. Commissiong believes understanding astrocyte-neuron biology will lead to a new generation of therapies brought to market for the treatment brain-related disorders. Dr. Commissiong holds a Ph.D. in Neurophysiology from the University of Southampton.